Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
19
|
pubmed:dateCreated |
1995-5-25
|
pubmed:language |
fin
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0012-7183
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
108
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1708-10
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1366200-Drug Therapy, Combination,
pubmed-meshheading:1366200-Furosemide,
pubmed-meshheading:1366200-Humans,
pubmed-meshheading:1366200-Hyperkalemia,
pubmed-meshheading:1366200-Kidney Failure, Chronic,
pubmed-meshheading:1366200-Potassium Chloride,
pubmed-meshheading:1366200-Spironolactone
|
pubmed:year |
1992
|
pubmed:articleTitle |
[Spironolactone, potassium chloride and hyperkalemia in patients with kidney failure].
|
pubmed:publicationType |
Letter,
Case Reports
|